The initial success of Viagra undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a uncertain picture. While early earnings were significant, the expiration of patents and the rise of discounted alternatives have eroded market share. Therefore, a thorough analysis of ongoing income